No Data Yet
On December 17, 2025, Novartis selected Salesforce's AI CRM platform for a global customer engagement overhaul, prompting a 1.27% rise in Salesforce (CRM) shares.
Pharmaceutical M&A deal value increased 31% year-over-year to $179.6 billion in 2025, driven by a series of mega-deals in the second half of the year as companies seek to replenish drug pipelines.
GSK plc is gaining significant investor attention after a series of positive regulatory updates in the U.S. and EU for key pipeline assets. These catalysts, combined with an imminent CEO transition, are reshaping the company's narrative from a stable dividend stock to a growth-oriented pipeline story.
Merck is strategically expanding its drug pipeline to mitigate the anticipated revenue loss from its blockbuster drug Keytruda's 2028 patent expiration. The market is focused on the execution risk and the commercial success of new assets needed to replace the multi-billion dollar revenue stream.
The global market for lateral flow assay (LFA) components is projected to reach $486.2 million by 2030, driven by the rising prevalence of infectious diseases and increasing demand for rapid, point-of-care diagnostics.
Medtronic has received two significant U.S. Food and Drug Administration (FDA) clearances for its Hugo robotic-assisted surgery (RAS) system and its MiniMed 780G diabetes management system, strengthening its competitive stance in the high-growth med-tech sector.
Roche's oral drug, giredestrant, reduced the risk of cancer recurrence or death by 30% in a Phase III study for early-stage breast cancer, positioning it as a potential new standard of care and disrupting the current market.
Recent clinical trial advancements in targeted and gene-editing therapies signal a significant shift in the oncology market. An innovative 'off-the-shelf' T-cell therapy has shown promise in early trials for leukemia, while major pharmaceutical firms are advancing pivotal studies for novel cancer drugs.
For the first time in decades, child mortality is projected to rise in 2025, reversing a long-term positive trend. The increase is primarily attributed to significant cuts in global health aid from wealthy nations, creating a critical funding gap for essential services like vaccines and primary care.